^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GAIA-102
i
Other names: GAIA-102, peripheral blood mononuclear cells, NPC-30
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GAIA BioMedicine, Nobelpharma
Drug class:
NK cell stimulant
Related drugs:
16d
GAIA-102-PD: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (clinicaltrials.gov)
P1/2, N=130, Recruiting, Kyushu University | N=96 --> 130 | Trial completion date: Jun 2027 --> Mar 2029 | Trial primary completion date: Dec 2026 --> Dec 2028
Enrollment change • Trial completion date • Trial primary completion date
|
CXCL11 (C-X-C Motif Chemokine Ligand 11)
|
Keytruda (pembrolizumab) • GAIA-102
over1year
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=56, Recruiting, Kyushu University | N=36 --> 56
Enrollment change
|
Opdivo (nivolumab) • GAIA-102
over3years
GAIA-102-PD: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (clinicaltrials.gov)
P1/2, N=96, Recruiting, Kyushu University
New P1/2 trial
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CXCL11 (C-X-C Motif Chemokine Ligand 11)
|
Keytruda (pembrolizumab) • GAIA-102
Share via
